מטרת המחקר: ECD patients with vemurafenib treatment seem to have a stable disease. This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been proposed for treating BRAF mutated histiocytoses. Other BRAF inhibitor interruption treatment should also be prospectively evaluated.
חוקר ראשי: Julien Haroche, M.D., Ph.D., HôpitalPitié-Salpêtrière, Paris FRANCE
פרטי יצירת קשר: Phone: +33 1 42 17 80 37 e-mail: julien.haroche@psl.aphp.fr
מעורבות המטופל הנדרשת: Patients and treating doctors are encouraged to contact Prof. Julien Haroche for more information.
מזהה באתר ClinicalTrials.gov: NCT02089724

